Cypress Asset Management Inc Editas Medicine, Inc. Transaction History

Cypress Asset Management Inc

  • $405 Million
  • Q2 2025

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 12, 2019
SELL
$18.19 - $31.79 $124,146 - $216,966
-6,825 Closed
0 $0
Q3 2018

Oct 19, 2018
SELL
$27.65 - $38.39 $4,424 - $6,142
-160 Reduced 2.29%
6,825 $217,000
Q2 2018

Jul 27, 2018
SELL
$31.4 - $41.01 $1,256 - $1,640
-40 Reduced 0.57%
6,985 $250,000
Q1 2018

May 14, 2018
BUY
$29.84 - $44.08 $209,626 - $309,662
7,025 New
7,025 $233,000

Others Institutions Holding EDIT

# of Institutions
218
Shares Held
45.5M
Call Options Held
476K
Put Options Held
338K
View Full List

About Editas Medicine, Inc.

EDIT Quotes by TradingView
  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $269M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Cypress Asset Management Inc Portfolio

Follow Cypress Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cypress Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Cypress Asset Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email